Formulation and evaluation of Olmesartan Medoxomil nanosuspension

Approximately forty percent of pharmaceuticals under development and seventy percent of drugs obtained in synthesis or high throughput screening are reported poorly soluble in aqueous media. As well as water, several of these compounds may be dissolved in organic solvents. The purpose of this study to solubility of the Olmesartan Medoxomil. Olmesartan Medoxomil nanosuspension was developed using Poloxamer 407 as a stabiliser, with a drug to stabiliser ratio of 1:1. The drug Olmesartan Medoxomil (0.1 percent w/v) and the polymer Poloxamer 407 (0.1 percent w/v) concentrations were combined to developed the optimized formulation. All trail batches were exposed to 15 min of probe sonication and three cycles of homogenization at 15 kpsi pressure, respectively. The improved formulation's particle size, polydispersity index, zeta potential, and entrapment efficiency were found as 199.8 nm, 0.211, −28 mV, and 98.96%, respectively. Scanning electron microscopy analysis revealed that the improved formulation had regular crystal shape, and X-ray diffraction tests confirmed that it was crystalline in nature. It has been concluded from this research that an Olmesartan formulation with enhanced saturation solubility and dissolution is feasible for commercialization. The goal of this research is to improve the saturation solubility and oral bioavailability of Olmesartan Medoxomil by administering the drug in the form of nano-sized crystals created by a combination of Probe sonication and High-Pressure Homogenization.